Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
Under the terms, Novavax will refund $123.8 million to the U.K. agency in quarterly payments of $10.3 million over three years, with the final payment due by June 30, 2027.On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract from July 1, 2022.
11月1日，諾瓦瓦克斯醫藥公司（納斯達克：NVAX）與英國衛生安全局（代表英國衛生和社會關懷國務大臣）簽署了一份解除與和解協議以及一份修訂協議，解決了雙方關於2022年7月1日更新的COVID-19疫苗供應合同的爭議。
As per the SEC filing, the agreement releases both parties from any claims related to that prior contract.
根據證券交易委員會提交的文件，該協議解除了雙方與先前合同相關的任何索賠。
As part of the settlement, Novavax and the U.K. Health Security Agency agreed to end the supply contract and settle disputed upfront payments Novavax previously received.
作爲和解的一部分，諾瓦瓦克斯醫藥公司和英國衛生安全局同意終止供應合同並解決之前諾瓦瓦克斯已收到的有爭議的預付款。
Under the terms, Novavax will refund $123.8 million to the U.K. agency in quarterly payments of $10.3 million over three years, with the final payment due by June 30, 2027.
根據協議，諾瓦瓦克斯將在未來三年內以每季度1030萬美元的金額向英國機構退款12380萬美元，最終付款截至2027年6月30日。
This amount includes $11.3 million in interest, which can be avoided if Novavax pays ahead of schedule. According to the amendment, the first quarterly payment is due on November 30, 2024.
此金額包括1130萬美元的利息，如果諾瓦瓦克斯提前支付，可以避免利息。根據修訂協議，第一筆季度付款截至2024年11月30日。
The two parties initially entered into a COVID-19 vaccine supply deal in 2020, and the United Kingdom government agreed to purchase 60 million doses of its COVID-19 vaccine.
雙方最初於2020年達成COVID-19疫苗供應交易，並英國政府同意購買諾瓦瓦克斯疫苗6000萬劑。
The company's protein-based adjuvanted shot NVX-CoV2373 was renamed Nuvaxovid after being authorized by the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2022.
該公司基於蛋白質的佐劑NVX-CoV2373在2022年被英國藥品和保健品管局（MHRA）授權後更名爲Nuvaxovid。
Recently, the FDA has placed a clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
最近，FDA對諾瓦瓦克斯的COVID-19-流感聯合（CIC）和獨立流感疫苗候選藥物的新藥調查申請（IND）提出了臨床暫停。
The clinical hold is due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial participant outside the U.S. who received the vaccine in January 2023.
臨床暫停是由於2023年1月在美國之外一名CIC第2階段試驗參與者出現嚴重不良事件（SAE）-機能神經病。
Earlier in October, the European Commission approved Novavax's updated 2024-2025 Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older to prevent COVID-19 in the European Union.
今年十月初，歐洲委員會批准了諾瓦瓦克斯醫藥經更新的2024-2025年 Nuvaxovid 新冠病毒疫苗（重組、佐劑化）(NVX-CoV2705)，用於歐盟境內12歲及以上人群注射霧化劑，以預防新冠病毒。
Price Action: NVAX stock is down 4.61% at $9.05 at last check Wednesday.
股價走勢：納瓦克斯醫藥股票在上週三最後一檢查時下跌4.61%，報9.05美元。
- Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
- 結直腸癌診斷專注的精密科學股票因年度業績指引疲弱而暴跌，分析師認爲存在引人注目的長期入市點。
Photo via Shutterstock
圖片來自shutterstock
譯文內容由第三人軟體翻譯。
